leadf
logo-loader
viewHumanigen, Inc.

Humanigen strikes partnership with life sciences group to launch lenzilumab for coronavirus if emergency use is granted

It would mean Humanigen would have immediate access to EVERSANA’s services

Cameron -
The drug is aimed at combating the 'cytokine storm', an overactive immune system response to the virus that precedes severe lung dysfunction and acute respiratory problems

Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) has announced a tie-up with life sciences services group EVERSANA, firing the starting gun on the commercial launch of its drug lenzilumab to treat hospitalized coronavirus (COVID-19) patients, if the candidate is granted emergency use authorization (EUA). 

On receipt of the authorization from regulator, the US Food and Drug Administration (FDA), Humanigen would have immediate access to EVERSANA’s services, which include marketing, medical information, and market access. 

READ: Humanigen wins US patent for Lenzilumab in preventing cytokine storm and neurotoxicity related to CAR-T cell therapy

As previously reported, Lenzilumab has shown positive trial results and has been tested on its ability to tackle the so-called 'cytokine storm', an overactive immune system response to the virus that precedes severe lung dysfunction and acute respiratory problems that is seen in COVID-19 patients. The drug is currently in two phase 3 trials.

"EVERSANA shares our tireless commitment to patients,” said Dr Cameron Durrant, the chief executive officer of Humanigen in a statement.

"We’ve matched our dedication to research and development in COVID-19 with a proven commercialization partner to ensure lenzilumab will reach patients quickly and efficiently following a potential EUA.”

EVERSANA currently serves more than 500 organizations, including innovative start-ups and established pharma groups.

Its CEO Jim Lang added: "While EVERSANA’s model can be applied to any therapy or indication, we have a moral obligation to help COVID-19 patients in distress, knowing that even with the promise of vaccines, there will be many patients who contract this virus and desperately need a treatment if hospitalized and hypoxic.”

Humanigen is a clinical-stage biopharma company, which is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

Roth rates stock a 'Buy'

Following the news, broker Roth rated Humanigen shares a 'Buy' and issued a 12 month price target of $25 (current price: around $17).

Analyst Tony Butler noted that the terms of Humanigen's agreement with EVERSANA were not disclosed, but highlighted other recent similar EVERSANA partnerships, including one struck with biopharma MacroGenics (NASDAQ:MGNX) for the commercialization of the latter's margetuximab for previously treated metastatic HER2-positive breast cancer in combination with chemotherapy.

Under the terms of that five year deal, MacroGenics books sales for margetuximab, while EVERSANA and MacroGenics equally share in funding EVERSANA’s commercialization expenses.

"...in exchange for co-funding these expenses, EVERSANA will earn future revenue share payments, which are capped at 125 percent of EVERSANA’s cumulative service fees," noted Butler.

Humanigen shares advanced over 9% in New York on the day to $18.87.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

3 min read